Christopher Roenfeldt

Mr. Roenfeldt joined Forte Biosciences in October 2020 and currently serves as its Chief Operating Officer. He has over 20 years of experience in clinical drug development including process development, engineering, capital construction, alliance and program management. Before joining Forte, Mr. Roenfeldt was an Alliance and Program Manager at Halozyme, overseeing multiple partnerships and development programs. Prior to that, Mr. Roenfeldt held positions of increasing responsibility and leadership at various biopharmaceutical companies, including Pfenex, Genentech, and Amgen. Mr. Roenfeldt received his B.S. in Chemical Engineering from the University of Colorado.